Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142-Reference-Cited by-同舟云学术

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Published:2022-10 Issue:10 Volume:33 Page:1052-1060
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

André T.,Lonardi S.,Wong K.Y.M.,Lenz H.-J.,Gelsomino F.,Aglietta M.,Morse M.A.,Van Cutsem E.,McDermott R.,Hill A.,Sawyer M.B.,Hendlisz A.,Neyns B.,Abdullaev S.,Memaj A.,Lei M.,Dixon M.,Kopetz S.,Overman M.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference24 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. 533P: a large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability;Tougeron;Ann Oncol,2017

3. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies;Venderbosch;Clin Cancer Res,2014

4. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer;Overman;J Clin Oncol,2018

5. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study;Overman;Lancet Oncol,2017

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the therapeutic promise of drug-repurposed-loaded nanocarriers: A pioneering strategy in advancing colorectal cancer treatment;International Journal of Pharmaceutics;2024-10

2. Colorectal cancer: Recent advances in management and treatment;World Journal of Clinical Oncology;2024-09-24

3. DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors;British Journal of Cancer;2024-09-13

4. The aminophospholipid transporter, ATP8B3, as a potential biomarker and target for enhancing the therapeutic effect of PD-L1 blockade in colon adenocarcinoma;Genomics;2024-09

5. High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy;ESMO Gastrointestinal Oncology;2024-09